Teclistamab
A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients
What will happen during the trial?
This is a single-arm, non-randomized, multicenter, prospective study of Teclistamab (TECVAYLI™), in adult patients with RRMM, in the post-marketing setting. Teclistamab (TECVAYLI™), the humanized IgG-4 PAA bispecific antibody, targets the CD3 receptor complex on T cells and BCMA on B-lineage cells.
This study will investigate the use of prophylactic tocilizumab to reduce the incidence and severity of CRS associated with teclistamab administration, to enable administration of the step-up dosing regimen of teclistamab in an outpatient setting.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 75 patients (estimated)
- Sponsors
- Sarah Cannon Research Institute
- Collaborators
- Janssen Research & Development LLC
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1746
- NCT Identifier
- NCT05972135
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.